logo
Share SHARE
FONT-SIZE Plus   Neg

Santarus NDA For Inflammatory Bowel Disease Therapy Uceris Accepted By FDA

Santarus Inc. (SNTS) Wednesday reported that the United States Food and Drug Administration, or FDA, accepted for filing its New Drug Application, or NDA, seeking approval to market Uceris tablets as a therapy to induce remission of mild to moderate active ulcerative colitis. The company anticipates the completion of the FDA's review by mid-October 2012.

The NDA seeks to market Uceris in a 9 milligram, or mg, tablet. Also, Cosmo Pharmaceuticals SpA-owned Cosmo Technologies Ltd., a collaborator in the development of Uceris, is now eligible to $4 million in cash or stock as a milestone payment, Santarus Said.

A form of inflammatory bowel disease, or IBD, ulcerative colitis can cause inflammations and ulcers along the colon, resulting in such effects as diarrhea, frequent bowel movements and bleeding. About 1.4 million Americans suffer from IBDs. Uceris is the trade name for budesonide, which is a corticosteroid with topical anti-inflammatory properties.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Volkswagen AG's all electric Microbus might be available in market by 2022. As per the plan it would be available first in California. Microsoft Corp. has unveiled a new Minecraft limited edition version of the Xbox One S console during its Gamescom press conference in Germany. The pixelated device comes with 1TB of storage. It includes a custom designed grass block console, Xbox Wireless Controller - Minecraft Creeper, Minecraft system sounds, vertical stand and transparent underside with Redstone circuit accents. HTC Corp. has cut the price of its Vive virtual reality headset by $200, bringing down the system's cost to $599. The company noted that the new entry price will make the system more accessible to the mass market across the globe. The price cut for the Vive VR headset comes after the Oculus Rift's $200 price cut recently.
comments powered by Disqus
Follow RTT